SAN DIEGO and MENLO PARK, Calif., May 6, 2026
Halozyme Therapeutics and Oruka Therapeutics announced a global exclusive collaboration and license agreement to develop ORKA-001 using Halozyme’s proprietary Hypercon™ technology, strengthening efforts to advance next-generation biologic therapies for psoriasis and inflammatory diseases. The agreement gives Oruka exclusive rights to utilize the Hypercon platform for its IL-23p19-targeting biologic candidate ORKA-001 and includes an option for one additional therapeutic target.
The collaboration highlights the growing importance of advanced biologic formulation and drug-delivery technologies in the pharmaceutical industry as companies increasingly seek methods to improve dosing convenience, reduce injection burden, and enhance long-term patient adherence. Industry analysts say partnerships focused on subcutaneous biologics and high-concentration injectable technologies are rapidly expanding as healthcare systems prioritize more patient-friendly treatment approaches.
Hypercon Technology Targets Improved Biologic Delivery
According to Halozyme, the proprietary Hypercon™ technology is an innovative microparticle platform designed to enable the hyperconcentration of biologics and injectable drugs, allowing the same therapeutic dose to be delivered in smaller injection volumes. The company stated that the technology is intended to support more convenient administration in both at-home and healthcare-provider settings while potentially improving the overall treatment experience for patients with chronic diseases.
Oruka Therapeutics is currently developing ORKA-001 for psoriasis and related inflammatory skin disorders, with the broader goal of achieving high rates of complete disease clearance through highly durable dosing regimens administered as infrequently as once or twice annually. Researchers believe advances in biologic formulation could significantly reshape treatment strategies for chronic inflammatory diseases by improving both convenience and adherence outcomes.
Advertisement
Halozyme President and Chief Executive Officer Dr. Helen Torley stated that the agreement represents the company’s second Hypercon collaboration announced in 2026, reflecting growing industry interest in the technology and its broad applicability across biologic therapeutic programs. Oruka CEO Lawrence Klein added that integrating Hypercon into Oruka’s product candidates may help strengthen the company’s ability to deliver differentiated biologic therapies for patients suffering from chronic skin diseases.
Collaboration Includes Milestones and Royalty Structure
Under the terms of the agreement, Oruka will provide Halozyme with an upfront payment along with potential future milestone payments tied to development, regulatory, and commercial achievements. Halozyme will also be eligible to receive mid-single-digit royalties on net sales of commercialized products utilizing Hypercon technology.
The deal further expands Halozyme’s growing drug-delivery technology portfolio, which already includes the commercially successful ENHANZE® platform powered by the proprietary enzyme rHuPH20. The company stated that ENHANZE has supported more than ten commercialized products across over 100 global markets through collaborations with major pharmaceutical and biotechnology companies including Roche, Pfizer, Takeda, Janssen, AbbVie, Eli Lilly, Bristol Myers Squibb, and argenx.
Halozyme also emphasized that Hypercon and Surf Bio’s polymer-based hyperconcentration technology are designed to complement ENHANZE by enabling the creation and subcutaneous delivery of highly concentrated biologics across a broader range of therapeutic modalities.
Biologic Drug Delivery Innovation Gains Momentum
The agreement underscores increasing global investment in biologic drug delivery technologies, particularly platforms capable of supporting at-home administration and reducing treatment complexity for chronic diseases. Experts say the pharmaceutical industry is placing growing emphasis on formulation innovation as biologics continue dominating pipelines in oncology, immunology, dermatology, and rare diseases.
Researchers believe technologies that improve injection tolerability, reduce dosing frequency, and enable more efficient subcutaneous administration may significantly influence future biologic commercialization strategies. Partnerships such as the Halozyme-Oruka collaboration are expected to accelerate development of next-generation patient-centric biologics capable of improving adherence, convenience, and long-term disease management outcomes.
Source: Halozyme Therapeutics, Oruka Therapeutics press release
